Loading news...
Executives from Alphatec (NASDAQ: ATEC) outlined their view of the spine surgery market, growth drivers, and recent financial progress during a conference discussion featuring Chief Financial Officer Todd Koning and Vice President of Finance and Head of Investor Relations Robert Judd. The conversation touched on investor questions about whether the company can sustain its growth rates
Alphatec Holdings, Inc. (ATEC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Over the course of 2025, Alphatec Holdings or "ATEC" has continued to outperform sales expectations and taken additional share in the $8 billion U.S. spinal disorder treatment market. In addition, the company has delivered vastly improved profitability and cash flow. While moderately lower growth expectations for 2026 appear to have impacted the stock price in recent weeks, I would consider the selloff a buying opportunity.
Alphatec Holdings, Inc. (NASDAQ: ATEC - Get Free Report) has been given an average rating of "Moderate Buy" by the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating
Alphatec (ATEC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to a loss of $0.23 per share a year ago.
Alphatec Holdings, Inc. (ATEC) Q4 2025 Earnings Call Transcript
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and year ended December 31, 2025, and business highlights. Fourth Quarter and Full-Year 2025 Financial Results Quarter Ended December 31, 2025 Year Ended December 31, 2025 Total revenue $213 million $764 million GAAP gross margin 70% 70% Non-GAAP gross margin 71% 7.
A CBOE veteran explains how prediction market signals move before stock prices - and how to use that gap to your advantage.
Granite Investment Partners LLC lessened its stake in Alphatec Holdings, Inc. (NASDAQ: ATEC) by 19.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,380,030 shares of the medical technology company's stock after selling 340,914 shares during
New York State Common Retirement Fund reduced its holdings in Alphatec Holdings, Inc. (NASDAQ: ATEC) by 6.6% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,251,065 shares of the medical technology company's stock after selling 88,135 shares during the quarter.
Shares of Alphatec Holdings, Inc. (NASDAQ: ATEC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twelve analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy
Emerald Advisers LLC lessened its stake in Alphatec Holdings, Inc. (NASDAQ: ATEC) by 2.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,638,882 shares of the medical technology company's stock after selling 45,452 shares during the quarter. Emerald Advisers
Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Craig E. Hunsaker, EVP, People & Culture at Alphatec Holdings, sold 32,584 shares for a transaction value of $679,050.56 at $20.84 per share on Dec. 10, 2025. The sale represented 2.53% of Hunsaker's direct holdings, reducing his stake from 1,289,142 to 1,256,558 shares.
Alphatec Holdings, Inc. (ATEC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ATEC Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment Theradaptive Initiates Series B to Advance Proprietary Protein-Engineering Technology CARLSBAD, Calif. and FREDERICK, Md.
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31, 2025. The Company also provided a financial outlook for full-year 2026. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Select Financial Results Fourth Quarter Ended December 31, 2025 Full Year Ended De.
Miles Patrick, the CEO of Alphatec Holdings, sold 100,000 shares of the company for about $2.1 million, according to a recent Form 4. This sale represented 1.82% of Miles Patrick's direct holdings, reducing direct ownership to 5.14 million shares.
Alphatec Holdings, Inc. (NASDAQ: ATEC - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $15.75 and traded as high as $21.20. Alphatec shares last traded at $20.98, with a volume of 1,149,093 shares traded. Analysts Set
COO Scott Lish sold 19,900 shares for a transaction value of $390,836 on Dec. 16, 2025. The sale reduced direct ownership to 641,432 shares (0.43% of shares outstanding).